- Current report filing (8-K)
28 2월 2009 - 6:52AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of
The
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
February 27, 2009 (February 23, 2009)
ALLOS
THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
Delaware
|
|
000-29815
|
|
54-1655029
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
|
|
11080 CirclePoint Road, Suite 200
Westminster, Colorado
|
|
80020
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code:
(303) 426-6262
Not applicable
(Former name or former address, if changed since
last report.)
Check the appropriate box
below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see
General Instruction A.2. below):
o
Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment
of Certain Officers; Compensatory Arrangements of Certain Officers.
Executive Officer Compensation and Equity Awards
At a meeting of the Compensation Committee of the
Board of Directors of Allos Therapeutics, Inc. (the
Company
)
held on February 23, 2009, the Compensation Committee (a) determined
and approved 2008 cash bonus awards and 2009 base salaries and target bonus
awards (expressed as a percentage of base salary) for the Companys named
executive officers (as defined in Item 402(a)(3) of Regulation S-K
promulgated by the Securities and Exchange Commission), and (b) granted
stock options and restricted stock units to the Companys named executive
officers pursuant to the Companys 2008 Equity Incentive Plan (the
Plan
). The 2008 cash
bonus awards and 2009 base salaries and target bonus awards (expressed as a
percentage of base salary) for the named executive officers, and the number of
stock options and restricted stock units granted to the named executive
officers, are set forth on Exhibit 10.1 attached hereto and incorporated
herein by reference.
The stock options and restricted stock units were
granted under and in accordance with the terms and conditions of the Plan,
which is filed as Exhibit 99.1 to the Companys Registration Statement on Form S-8
(No. 333-151882). The stock options
are exercisable for a term of ten (10) years measured from the date of grant at
an exercise price of $6.40, which equals the closing price of the Companys
common stock as quoted on the Nasdaq Global Market on the date of grant. The stock options vest over a four (4) year
period, with 25% of such options vesting one (1) year after the date of
grant and 75% of such options vesting in equal monthly installments thereafter
over the next three (3) years, subject to the named executive officers
continued employment with the Company through such vesting dates. The form of option grant notice and agreement
relating to the stock option awards conforms to the Companys standard form of
option grant notice and agreement approved by the Companys Board of Directors
for use under the Plan, which such standard form of option grant notice and
agreement is filed as Exhibit 99.2 to the Companys Registration Statement
on Form S-8 (No. 333-151882).
The restricted stock units vest in equal installments on each of the
first four (4) anniversaries of the date of grant, subject to the named
executive officers continued employment with the Company through such vesting
dates. The form of restricted stock unit
grant notice and agreement relating to the restricted stock unit awards and
approved by the Companys Board of Directors for use under the Plan is attached
hereto as Exhibit 10.2 and incorporated herein by reference.
The Compensation Committee also reviewed and
approved, at the same meeting, the 2009 corporate and individual performance
objectives to be evaluated by the Compensation Committee in connection with the
determination of 2009 bonus awards for the named executive officers. The 2009 corporate objectives generally
target the achievement of specific research and development, commercial
planning, manufacturing and corporate development milestones that are
considered to be important to the achievement of the Companys long-term
strategic goals. The 2009 individual
objectives for the named executive officers (other than the Companys Chief
Executive Officer, whose bonus is tied entirely to the achievement of corporate
objectives) focus on contributions that are generally consistent with and
support the corporate objectives or are otherwise intended to contribute to the
success of the Company.
The 2008 cash bonus award and 2009 target bonus
award (expressed as a percentage of base salary) for the Companys Chief
Executive Officer, as well as the Companys 2009 corporate objectives, were
also reviewed and approved by the full Board of Directors at a meeting held on February 23,
2009.
Change in Control Severance Benefit Schedule under the Companys
Severance Benefit Plan
The Companys Board of Directors has previously
adopted a Severance Benefit Plan to provide for the payment of severance
benefits to all full-time employees, including the Companys named executive
officers, who do not otherwise have separate employment agreements and whose
employment with the Company is involuntarily terminated due to a group
termination, the closure or reorganization of a facility or operation, a change
in ownership, or such other event, but only to the extent the Company
specifically identifies such an event in a severance benefit schedule approved
by the Companys Board of Directors as a termination of employment subject to the
provisions of the Severance Benefit Plan.
2
On February 24, 2009, the Board of Directors
approved an amended and restated Change in Control Severance Benefit Schedule
(the
Schedule
) under the Companys
Severance Benefit Plan to provide for the payment of severance benefits to
eligible employees whose employment is involuntarily terminated in connection
with a change in control of the Company.
The Schedule provides that if the Company (or any surviving or acquiring
corporation) terminates an eligible employee without just cause or the eligible
employee resigns for good reason within two (2) months prior to or six (6) months
following the effective date of a change in control of the Company, and upon the
employees execution of a general release agreement releasing the Company from
all claims known or unknown that the employee may have against the Company, the
eligible employee will be entitled to receive the following severance benefits:
·
If the eligible employee holds a position
with the Company of director or above, the Company shall pay the employee a
lump-sum cash payment equal to (i) six (6) months of the employees
base salary then in effect (excluding overtime and bonuses) plus an additional
two (2) weeks base salary for each twelve (12) months of continuous
service with the Company, up to a maximum of fifty-two (52) weeks, plus (ii) the
employees target bonus award for the year in which the employees employment
terminates, prorated through the date of termination.
·
If the eligible employee holds a position
with the Company below director, the Company shall pay the employee a lump-sum
cash payment equal to (i) three (3) months of the employees base
salary then in effect (excluding overtime and bonuses) plus an additional two (2) weeks
base salary for each twelve (12) months of continuous service with the Company,
up to a maximum of fifty-two (52) weeks, plus (ii) the employees target
bonus award for the year in which the employees employment terminates,
prorated through the date of termination.
·
Full acceleration of vesting of any
outstanding stock options and restricted stock issued to the eligible employee.
·
Payment of premiums for the eligible employees
group health insurance COBRA continuation coverage after the date of
termination for the number of weeks that are used to determine the amount of
the eligible employees cash severance as described above.
·
Outplacement assistance through an outside
organization as a resource to aid in the eligible employees career transition.
The Companys Severance Benefit Plan and the
Schedule are attached hereto as Exhibits 10.3 and 10.4, respectively, and each
of them is incorporated herein by reference.
Item 9.01
Financial Statements and Exhibits.
(d) Exhibits.
10.1
|
|
Executive
Compensation and Equity Awards.
|
|
|
|
10.2
|
|
Form of
Restricted Stock Unit Grant Notice and Agreement under the 2008 Equity
Incentive Plan.
|
|
|
|
10.3
|
|
Allos
Therapeutics, Inc. Severance Benefit Plan, as amended and restated
effective December 11, 2007.
|
|
|
|
10.4
|
|
Allos
Therapeutics, Inc. Change in Control Severance Benefit Schedule, as
amended and restated effective February 23, 2008.
|
3
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this
report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: February 27, 2009
|
|
ALLOS
THERAPEUTICS, INC.
|
|
|
|
|
|
|
|
By:
|
/s/
Marc H. Graboyes
|
|
|
Marc
H. Graboyes
|
|
Its:
|
Senior
Vice President, General Counsel
|
4
EXHIBIT
INDEX
Exhibit No.
|
|
Description
|
|
|
|
10.1
|
|
Executive
Compensation and Equity Awards.
|
|
|
|
10.2
|
|
Form of
Restricted Stock Unit Grant Notice and Agreement under the 2008 Equity Incentive
Plan.
|
|
|
|
10.3
|
|
Allos
Therapeutics, Inc. Severance Benefit Plan, as amended and restated
effective December 11, 2007.
|
|
|
|
10.4
|
|
Allos
Therapeutics, Inc. Change in Control Severance Benefit Schedule, as
amended and restated effective February 23, 2008.
|
5
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024